GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baxalta Inc (NYSE:BXLT) » Definitions » EPS (Diluted)

Baxalta (Baxalta) EPS (Diluted) : $1.21 (TTM As of Mar. 2016)


View and export this data going back to 2015. Start your Free Trial

What is Baxalta EPS (Diluted)?

Baxalta's Earnings per Share (Diluted) for the three months ended in Mar. 2016 was $0.21. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 was $1.21.

Baxalta's EPS (Basic) for the three months ended in Mar. 2016 was $0.21. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2016 was $1.22.

Baxalta's EPS without NRI for the three months ended in Mar. 2016 was $0.21. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2016 was $1.19.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Baxalta EPS (Diluted) Historical Data

The historical data trend for Baxalta's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxalta EPS (Diluted) Chart

Baxalta Annual Data
Trend Dec12 Dec13 Dec14 Dec15
EPS (Diluted)
- - - 1.30

Baxalta Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.40 0.41 0.45 0.14 0.21

Competitive Comparison of Baxalta's EPS (Diluted)

For the Biotechnology subindustry, Baxalta's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baxalta's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baxalta's PE Ratio distribution charts can be found below:

* The bar in red indicates where Baxalta's PE Ratio falls into.



Baxalta EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Baxalta's Diluted EPS for the fiscal year that ended in Dec. 2015 is calculated as

Diluted EPS (A: Dec. 2015 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(956-0)/683.000
=1.40

Baxalta's Diluted EPS for the quarter that ended in Mar. 2016 is calculated as

Diluted EPS (Q: Mar. 2016 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(145-0)/690.000
=0.21

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baxalta  (NYSE:BXLT) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Baxalta EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Baxalta's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Baxalta (Baxalta) Business Description

Traded in Other Exchanges
N/A
Address
Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.
Executives
Gail D Fosler director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
John Glasspool officer: See Remarks C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Dagmar Rosa-bjorkeson officer: EVP and President, Biosimilars C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
David D. Meek officer: EVP and President, Oncology 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Peter G Edwards officer: SVP and General Counsel C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Robert J. Hombach officer: EVP. CFO and COO C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Blake E Devitt director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Wayne T Hockmeyer director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anne-marie Law officer: EVP & Head of Human Resources C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Stroucken Albert P L director BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Gavin James R Iii director BAXTER INTERNATIONAL INC, ONE BAXTER PARKWAY, DEERFIELD IL 60015
John D Forsyth director C/O BAXTER INTERNATIONAL, ONE BAXTER PARKWAY, DEERFIELD IL 60015
Ludwig Hantson director, officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921

Baxalta (Baxalta) Headlines

From GuruFocus

Is Baxalta a Good Spin-Off Opportunity?

By Raman Minhas Raman Minhas 10-15-2015

Baxalta: A Rare Undervalued Biopharmaceutical Company

By Ben Reynolds Ben Reynolds 07-23-2015

Third Avenue Management Comments on Baxalta

By Holly LaFon Holly LaFon 03-29-2016

Daniel Loeb Comments on Seven & i Holdings

By Holly LaFon 11-03-2015

Third Avenue Management Comments on Baxalta

By Holly LaFon Holly LaFon 12-10-2015

Third Avenue Buys Baxter Spin-Off

By Kyle Ferguson Kyle Ferguson 01-17-2016

Tweedy Browne Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-27-2016

Keeley Funds Comments on Baxalta Inc.

By Holly LaFon Holly LaFon 02-03-2016

Jeff Auxier Sells Precision Castparts, AT&T, Microsoft

By Tiziano Frateschi Tiziano Frateschi 06-23-2016